Blue Horseshoe Stocks: Form-4 Alert & More

Snap, Inc. SNAP – Update

Even as the markets got crushed yet again yesterday despite it appearing as if the worst of the downturn was over, SNAP still managed to produce gains in our updated options trading targets.

It was in our premarket report yesterday that we were updating readers on the previous idea we had with the SNAP $16-17.50 Calls, which made moves ranging from 335-700% the day prior.

The stock had risen by such a large margin that we rolled up our potential strike prices to the $21-22.50 levels, and we got very nice activity out of half of those calls to keep our success with the SNAP options chain rolling.

The $21 Calls ran from .04-.32, for a fantastic 700% rip, while the 21.50’s made a 400% from .03-.15.
________

Fresh Options Idea:

Provided the SPY holds above 259.50 we’ll be interested in the SPY Weekly $260.50-262 Calls*

*Please do not attempt to trade weekly options on a Friday unless you are an expert level trader with disposable funds.



LendingClub Corp. LC

With turmoil in the markets persisting, this is a time when we want to stick to our technicals, and look for stocks that are currently boasting the type of chart setups we routinely scan for, and LC currently matches the profile.

The stock has come down to double-bottom with a gap to fill to the upside, as you can see on the included snapshot. We feel that over the next few weeks, LC could be in line for a solid recovery.

In addition to the stock itself, we’re going to radar a pair of options contracts to track over a more extended period of time, with the LC 03/16 $3.50 & $4 Calls.


Seattle Genetics, Inc. SGEN – Form-4 Alert

While we’re on the subject of bottom-plays, we’ve got SGEN hitting our scanner this morning. We’ll include a chart snapshot of this one as well, so you can see what we find so attractive about it. We’ve got a triple-bottom formation happening with the stock coming down to he $50-range, and a recent track record of the type of volatility we’re after.

To sweeten the pot, a major Form-4 buy came in the last week at $52, to the tune of $200M (View EDGAR Filing) in addition to a multi-program immuno-oncology collaboration with Pieris Pharmaceuticals announced this morning.

We’re going to track the SGEN 03-16 $50 Calls in the days and weeks ahead.


Extended Watchlist:
PIRS, AVIN, CTRL, CFMS, CNET, INPX

Blue Horseshoe Stocks: NFLX Options & More

Sorrento Therapeutics, Inc. SRNE

Recently we’ve been delving back into our reports from late 2017, to review the ones that have made notable moves, and next up on the list SRNE.

We last signaled our interest in this as a bottom-watch play back on November 16th, and while it took a couple weeks for it to get out of its sideways-trading funk, the beginning of December brought the start of a fantastic run from an ultimate low of 2.15 that has persisted into the present. Yesterday the stock reached a new annual high of 8.05 (highest PPS since October ’16), marking an increase of 274%

This most recent push in what has definitely been a steady but sharp rise of the past six weeks may have been helped along by Celgene’s (CELG) buyout of Juno Therapeutics (JUNO), which share a market space with SRNE. The company also has some promising treatments in its pipeline.

Volume has recently been ramping up in a big way, too, so we’ll definitely continue to have an eye on this stock’s activity.


Netflix, Inc. NFLX – Options Idea

We’re always looking for a good opportunity to make some quick gains in the wake of a big company’s earnings, and NFLX is one that we’ve had quite a bit of experience with in that arena.

That’s why we’re going to enter an idea into the log this morning in the NFLX Weekly $247.50-255 Calls as the company posted a promising report including the addition of more than eight million new subscribers even despite its recent price increases.

Shares of NFLX broke a double top and are in blue skies, hitting a new all time high, so we’re very interested to track the ideas we’ve identified. They may be able to furnish us with some impressive gains.


Extended Watchlist:
CNET, ROKU, FATE, RMD, FNJN, VYGR

Blue Horseshoe Stocks: XXII Update & More

22nd Century Group, Inc. XXII

It was back on November 7th that we highlighted a large group of cannabis stocks, and professed our unyielding interest in the space as a whole. XXII was among those that we specifically highlighted as promising pot stocks in that report, and despite it being more than 8 weeks later, the stock has continually bulled its ways to new highs ever since.

We wanted to swing back around this morning to outline the excellent run it has been on since November. Subsequent to our report on the 7th the stock saw an absolute bottom of 2.00 even before beginning its months-long ascent. Yesterday the stock reached yet another new high of 3.85, marking an overall upswing of 93%


Yield10 Bioscience, Inc. YTEN

Following a huge single session run in early December, YTEN was unable to hold onto any of the ground it had gained, and with the ‘help’ of a massive public offering, continued to descend until recently.

This week, the stock has begun to show signs of a bottom bounce, and we’re going to want to add it to the radar on a recovery watch. As you can see form the chart snapshot included below, there is a lot of room for a potential surge, including a gap to fill to the upside.


Extended Watchlist:
NVAX, RKDA, SDRL, CRBP, SQ, CHFS, NBEV, SIEN, CNET